Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHINE: Super local hypofractionated radiotherapy plus tislelizumab in stage IA nasopharyngeal carcinoma
ChiCTR2500112244Phase 2Not yet recruiting
- Sponsor
- Cancer Hospital, Chinese Academy of Medical Sciences
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in nasopharyngeal carcinoma (NPC), sponsored by Cancer Hospital, Chinese Academy of Medical Sciences. Primary endpoint: 3-month clinical complete remission rate. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2500112244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112244.